Zerodha CEO Nithin Kamath highlighted the transformative potential of weight-loss drugs Ozempic and Mounjaro, which help in ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

I n addition to their origins as treatment for type 2 diabetes, GLP-1 receptor agonists like Ozempic and Wegovy are often ...

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Novo has been trying to strengthen its foothold in the potential $150 billion obesity market through the development of ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Their project, called Phytogene, harnesses the power of “biopharming” — a method that transforms plants into living drug ...

Zerodha’s Nithin Kamath sparks debate on Ozempic, Mounjaro & their game-changing impact on obesity, addiction & industries. Is India ready for this shift?

Research shows that glucagon-like peptide-1 receptor agonists (or GLP-1s – think Ozempic or similar medications) are changing ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...